Psychedelic Research in
Malaysia
Malaysia has a restrictive framework for classical psychedelics and most entheogenic compounds, with access for medical use generally limited to approved research or controlled medicines. In practice, the clearest legal clinical pathway in this space is esketamine for treatment-resistant depression; ketamine itself is also used in clinical settings, mainly as an anaesthetic and in some specialist practice contexts.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Malaysia.
- 1
The public-facing Malaysian evidence base is much stronger for ketamine/esketamine than for classic psychedelics, suggesting the national research pathway is currently pharmacologically adjacent rather than psychedelic-specific.
- 2
Malaysia's MOH materials indicate controlled-drug oversight rather than an open-access model, so any psychedelic-related treatment claim should be treated cautiously unless tied to a named study or licensed product.
- 3
A Malaysian case series and literature review on maintenance ketamine for treatment-resistant depression shows local clinician interest, but it is small, observational evidence rather than proof of standardised service delivery.
- 4
The most concrete psychiatric policy signal is MOH guideline language on esketamine for treatment-resistant depression, which suggests official awareness of rapid-acting antidepressant approaches, not approval of classic psychedelics.
- 5
No active linked trials, stakeholders or events implies the country page should be framed as a cautious regulatory/research snapshot rather than an ecosystem with visible current momentum.
Research Snapshot
Blossom currently tracks 5 psychedelic clinical trials connected to Malaysia.
- Active trials
- 0
- Total trials
- 5
- Stakeholders
- 0
- Events
- 0
None marked active
Country-linked records
No linked stakeholders
No linked events
Top Compounds
- Esketamine(5)
Top Study Topics
- Treatment-Resistant Depression (TRD)(3)
- Major Depressive Disorder (MDD)(2)
Medical Access Snapshot
Malaysia maintains a restrictive national framework for classical and novel psychedelics: most serotonergic/entheogenic compounds (psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT, ibogaine, ayahuasca) are treated as controlled/illegal under national drug control policy with no authorized medical use outside approved research. Esketamine (SPRAVATO) is registered in Malaysia and is available through regulated medical channels; racemic/clinical ketamine is a controlled medicine used in clinical settings (largely as an anaesthetic and off-label in...
Regulatory Status
Malaysia's Ministry of Health maintains a controlled-substance framework under the Dangerous Drugs Act 1952, and its pharmaceutical services pages indicate central control of dangerous drugs. For psychedelics, the practical position is restrictive: psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT, ibogaine and ayahuasca are not presented as having routine medical access, and any use would generally fall outside normal care and into research/forbidden-control territory. By contrast, MOH clinical guidance for major depressive disorder discusses intranasal esketamine as an augmentation option for treatment-resistant depression, but that does not by itself prove broad patient access or reimbursement; ketamine use remains context-specific and regulated.
Country Details
- Region
- Asia
- Last updated
- 18 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Malaysia maintains a restrictive national framework for classical and novel psychedelics: most serotonergic/entheogenic compounds (psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT, ibogaine, ayahuasca) are treated as controlled/illegal under national drug control policy with no authorized medical...
Open access guide →Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Malaysia.